Other
Hypersomnia
7
Pipeline Programs↗
2
Active Trials↗
4
Companies Involved↗
Hypersomnia is an early-stage landscape with 7 programs across 4 companies. The most active players are Jazz Pharmaceuticals, AbbVie, Axsome Therapeutics, Inc.. 1 therapy is approved with 1 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 31
Approved1
Analysis
Trial Status
7
clinical trials
Completed4 · 57%
Withdrawn1 · 14%
Active, not recruiting1 · 14%
Recruiting1 · 14%
Clinical Trials
Trial Activity
7 trials
RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia)
Active, not recruiting·—·Phase 2·NCT06404099·361 enrolled
Clarithromycin for the Treatment of Hypersomnia
Completed·—·Phase 2·NCT01146600·26 enrolled
Flumazenil for the Treatment of Primary Hypersomnia
Completed·—·Phase 1/2·NCT01183312·10 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)